At present, the clinical diagnosis of Parkinson’s disease does not rely on imaging or laboratory tests. The auxiliary tests available for clinical application do not provide direct diagnostic value, but can provide negative evidence, except for diseases similar to Parkinson’s disease. 1. Brain CT examination and brain MRI examination have no characteristic changes in either the early stages or the late stages of Parkinson’s disease. However, CT brain examination can detect the following abnormalities in patients with Parkinson’s syndrome: basal ganglia calcification, hydrocephalus, cerebral atrophy, subcortical white matter lesions, cerebral infarction, etc. MRI examination has high resolution ability and is more clinically significant than CT brain in the diagnosis and differential diagnosis of this disease. MRI can detect the following abnormalities: (1) diffuse brain atrophy and subcortical white matter degeneration; (2) narrowing of the substantia nigra band; (3) focal high signal in the substantia nigra and pallidum; (4) focal atrophy in the substantia nigra and pallidum; (5) occasional bilateral iron deposition in the nucleus accumbens, forming the “tiger’s eye sign”, which is a rare pallidum-pallidum pigment degeneration disease, suggesting The patient has Parkinson’s syndrome. These can be used as evidence for differential diagnosis or denial of Parkinson’s disease, and are meaningful for the diagnosis of Parkinson’s syndrome and Parkinson’s superimposed syndrome. 2. The patient’s routine blood, liver and kidney function, blood glucose, lipids and serum potassium, sodium, calcium, iron and copper tests were normal; only the metabolite of dopamine, homovanillic acid (HVA), was decreased in cerebrospinal fluid and urine, and the metabolite of 5-hydroxytryptamine was also decreased in cerebrospinal fluid. However, these tests are not important for clinical diagnosis and have only been used as indicators in some studies. To date, there is no specific instrument or laboratory test that can directly confirm the diagnosis of Parkinson’s disease. 3. One test that may be useful for early diagnosis is positron emission scanning, or PET for short. current studies have found that the application of a [18F]-fluorodopa reagent injected into the body, followed by PET scanning, can confirm the diagnosis of early Parkinson’s disease. Because [18F]-fluorodopa is a similar compound to levodopa, it can cross the blood-brain barrier and be taken up by dopaminergic neurons, thus indirectly reflecting the number of nigrostriatal dopamine neurons and the severity of the disease. Some studies have shown that the accumulation of [18F]-fluorodopa in the striatal region is significantly lower in Parkinson’s disease patients than in normal subjects, and the shell nucleus contralateral to the lateral Parkinson’s disease symptoms is only 57-80 of the normal value. but the test is very expensive, and it is largely not used clinically to diagnose Parkinson’s disease.